Study of high mobility group box 1 protein level in patients with diffuse large b cell lymphoma

Abstract

Background: Diffuse large B-cell lymphoma (DLBCL) has been the most common kind of non-Hodgkin lymphoma (NHL), representing for roughly 24% of new instances per year. The HMG box 1 protein is a nuclear DNAbinding protein that was identified more than thirty years ago. It binds to DNA and functions as a cofactor in the transcription of genes. Overexpression of HMGB1 was being discovered in many cancers, including breast cancer, gastric cancer, and non-Hodgkin lymphoma. Aim of the study: to see how high mobility group box 1 protein levels are affected by DLBCL and how chemotherapy affects HMGB1 levels in DLBCL patients. Patients and Methods: This study was conducted out in oncology department of Al-Hussein University hospital. Two groups of patients were formed. Group (A): composed of 35 patients with DLBCL for whom pre-treatment and post-treatment level of HMGB1 protein were measured. Group (B): composed of 35 normal subjects act as a control group. All procedures followed Al-Azhar University Ethical Committee regulations. Results: there is statistically significant improvement after chemotherapy as t value equaled (8.632) with P-value (0.000). Also, when comparing pre-value with normal, paired t test equaled (10.16) with P-value (0.000). Using ROC curve, it was stated that area under the curve equaled 1 with standard error 0 and P=0.017. Conclusion:The HMG box 1 protein is a significant indicator in patients with DLBCL.